🎉 Today marks a truly historic moment – not just for our company, but for the entire spinal cord injury (SCI) community. After more than a decade of pioneering research and unwavering dedication, we have received FDA de novo classification and authorization to market the ARC-EX® System, the world's first non-invasive spinal cord stimulation system proven to improve strength and sensation after chronic SCI. 💫 Here are some key highlights of the ARC-EX System: ⭐️ 90% of clinical trial participants showed improved strength or function* in clinical trials ⭐️ Benefits seen up to 34 years post-injury* in clinical trials ⭐️ Named a @TIME Magazine Best Invention of 2024 For the first time ever, there is an approved therapy to improve hand strength and sensation for people with SCI. This recognition is particularly meaningful because it acknowledges more than just technological innovation – it validates the benefits of this therapy for the millions of people worldwide who dream of regaining movement and independence after SCI. We thank the entire SCI Community for supporting us in our journey to develop and introduce this breakthrough technology. Together, we are not just developing devices; we are reshaping what is possible after spinal cord injury. 🚀 🔗 For more details, read our press release (link in comments). *Moritz, Chet, et al. “Non-invasive spinal cord stimulation for arm and hand function in chronic tetraplegia: a safety and efficacy trial.” Nature Medicine. 2024. #EmpoweringMovement #SCI #MedicalBreakthrough #Innovation Note: The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Please note that all other ONWARD Medical devices and therapies, including ARC-IM®, ARC-BCI®, and ARC Therapy™ with brain-computer interfaces (BCIs), are investigational and not commercially approved. Patient testimonials reflect individual experiences and outcomes, which may vary. Please review the full product label and clinical study data.

💫 Scientific innovation in #neurotech took the world diplomatic stage last month as our co-founders and advisors, neuroscientist @gcourtine and neurosurgeon @Jocelyne_Bloch, addressed the @UN Security Council. 🇺🇳 The pair shared their knowledge about the latest breakthroughs in brain-computer interface (BCI) technology, leveraging their groundbreaking work developing a DigitalBridge™ to enable though-driven movement after paralysis. The Security Council discussed how scientific developments can contribute to global peace and security. Swiss Federal Councillor @ignaziocassis chaired the meeting after Switzerland introduced the topic for Council discussions.🇨🇭 The opportunity highlights the profound impact scientific advances can make on daily lives and world affairs. We feel privileged that our co-founders and collaborators were part of this important conversation. 🌏 #EmpoweringMovement #SCI #BCI #UNSecurityCouncil #WorldPeace Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.